Version 2 2023-06-12, 09:11Version 2 2023-06-12, 09:11
Version 1 2023-06-09, 18:36Version 1 2023-06-09, 18:36
journal contribution
posted on 2023-06-12, 09:11authored byAlexander Szubert, Sarah Lou Bailey, Graham S Cooke, Tim Peto, Martin LlewelynMartin Llewelyn, Jonathan D Edgeworth, A Sarah Walker, Guy E Thwaites
Adjunctive rifampicin did not reduce failure/recurrence/death as a composite endpoint in the ARREST trial of Staphylococcus aureus bacteraemia, but did reduce recurrences. We investigated clinically-defined 14-day treatment failure, and recurrence and S. aureus-attributed/unattributed mortality by 12-weeks to further define their predictors